Australia has an enviable record in the assessment of new pharmaceutical products, based on the principles of cost-effectiveness.8 However, the assessment of new surgical interventions, devices and other technology is not comprehensive and lacks the cost-effectiveness rigour applied to pharmaceutical products and vaccines.